U.S. markets closed
  • S&P 500

    4,356.45
    -53.68 (-1.22%)
     
  • Dow 30

    34,297.73
    -66.77 (-0.19%)
     
  • Nasdaq

    13,539.29
    -315.83 (-2.28%)
     
  • Russell 2000

    2,004.03
    -29.48 (-1.45%)
     
  • Crude Oil

    85.16
    -0.44 (-0.51%)
     
  • Gold

    1,847.90
    -4.60 (-0.25%)
     
  • Silver

    23.86
    -0.03 (-0.13%)
     
  • EUR/USD

    1.1307
    -0.0023 (-0.20%)
     
  • 10-Yr Bond

    1.7830
    +0.0480 (+2.77%)
     
  • GBP/USD

    1.3508
    +0.0018 (+0.13%)
     
  • USD/JPY

    113.8700
    -0.0900 (-0.08%)
     
  • BTC-USD

    36,765.95
    +259.73 (+0.71%)
     
  • CMC Crypto 200

    831.82
    +11.23 (+1.37%)
     
  • FTSE 100

    7,371.46
    +74.31 (+1.02%)
     
  • Nikkei 225

    27,131.34
    -457.03 (-1.66%)
     

How Much Did Solid Biosciences'(NASDAQ:SLDB) Shareholders Earn From Share Price Movements Over The Last Three Years?

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • SLDB

As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So take a moment to sympathize with the long term shareholders of Solid Biosciences Inc. (NASDAQ:SLDB), who have seen the share price tank a massive 90% over a three year period. That'd be enough to cause even the strongest minds some disquiet. Shareholders have had an even rougher run lately, with the share price down 28% in the last 90 days.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

Check out our latest analysis for Solid Biosciences

Solid Biosciences isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

This free interactive report on Solid Biosciences' balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

Over the last year Solid Biosciences shareholders have received a TSR of 16%. It's always nice to make money but this return falls short of the market return which was about 41% for the year. The silver lining is that the recent rise is far preferable to the annual loss of 24% that shareholders have suffered over the last three years. It could well be that the business is stabilizing. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Solid Biosciences is showing 5 warning signs in our investment analysis , and 2 of those are significant...

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.